Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Interpore Cross

This article was originally published in The Gray Sheet

Executive Summary

Launch of the firm's Pro Osteon 500R resorbable bone void filler is anticipated by year end following FDA market go-ahead, announced Sept. 29. Intended for bony voids or gaps in the skeletal system, including the extremities, spine and pelvis, the product's calcium carbonate pores are layered with calcium phosphate, allowing for "biocompatibility along with predictable resorption characteristics," Interpore says. The Irvine, California-based firm plans to combine the product with its autologous growth factors technology, and looks to market a next-generation product in mid-1999
UsernamePublicRestriction

Register

MT010710

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel